*sponsored by
Whew! It’s a bloodbath out there — trade safe… Meanwhile, there are still some big movers today. Check ‘em out. And check US out in the Market Masters Trade Room 🔥.
(Don’t forget Jeff’s Bullseye is going out right before the market opens. What’s he gonna pick??? Get on his list quick to find out!)
FOCUS LIST🔎
ETHD – Up over 40% in the pre-market, as market turmoil has this inverse Ethereum ETF soaring
ZVRA – Up over 20% in pre after FDA Advisory Committee votes favorably that the data support Arimoclomol as effective treatment for patients with Niemann-Pick Disease Type C
MIRA – Up over 10% in pre after Ascendiant Capital initiates coverage on Mira Pharmaceuticals with Buy rating, announces price target of $11
*sponsored by magnifi
Enhance your investing strategy with advanced AI technology.
Magnifi is the world’s first AI designed to help you invest.
With Magnifi, you have access to a powerful conversational AI assistant, an investment search engine, interactive financial planning tools, and a commission-free brokerage.
With this powerful tool in your pocket (or on your desktop), you can do faster and better research, get help making financial decisions, manage your portfolio, and more.
Think of Magnifi as a co-pilot for your investing — like a Siri or Alexa that went to investment school. Magnifi analyzes your current financial status and helps you make informed investment decisions that bring you closer to your goals.
*Advisory services are offered through Magnifi LLC, an SEC Registered Investment Advisor. Being registered as an investment adviser does not imply a certain level of skill or training.
HOTLIST🔥
ETHD – Up over 40% in the pre-market, as market turmoil has this inverse Ethereum ETF soaring
ETHD is the Proshares UltraShort Ether ETF (ETHD). This is an inverse or short ETF which usually trades inversely to how Ethereum or the price of ETH is performing.
Crashes in Japanese markets this morning due to strengthening in the YEN have markets in turmoil before the open. Crypto has not been left unscathed and Ethereum/USD traded down over 20% in the pre-market.
Due to the large fall the Proshares UltraShort Ether ETF traded up over 40% in the pre-market this morning, making new all-time highs.
The first target for bulls is the pre-market high at $83.75.
Above it targets to the upside are $85, $90 and $100.
Below $83.75, targets to the downside are $80, $75 and $70.
I’d expect to see increased volatility today with the VIX at elevated levels and margin calls rampant throughout markets.
ZVRA – Up over 20% in pre after FDA Advisory Committee votes favorably that the data support Arimoclomol as effective treatment for patients with Niemann-Pick Disease Type C
Zevra Therapeutics, Inc. (ZVRA) discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
In the after-hours on Friday, the company announced that he U.S. Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C (NPC).
The committee’s recommendation will be considered by the FDA as it completes its independent review of the Arimoclomol NDA; however, the feedback from the GeMDAC is not binding upon the Agency. The arimoclomol NDA has been assigned a Prescription Drug User Fee Act (PDUFA) action date of September 21, 2024.
ZVRA stock traded up over 20% in the pre-market in reaction to the news.
The $7.15 area has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $7.50, $8, $9 and then the pre-market high at $9.44. Beyond that, $10.50 and $11.50 come into play.
Below $7.15, targets to the downside are $7, $6.50 and then a gap fill at $6.30 with $5.50 below that.
MIRA – Up over 10% in pre after Ascendiant Capital initiates coverage on Mira Pharmaceuticals with Buy rating, announces price target of $11
MIRA Pharmaceuticals, Inc. (MIRA) operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
One focuses on an oral Ketamine treatment and the other an oral pharmaceutical marijuana treatment.
In the pre-market this morning, it was reported that Ascendiant Capital initiated coverage on Mira Pharmaceuticals with a Buy rating and announced a price target of $11.
The price target represents an increase of over 400% of MIRA’s closing price on Friday of $2.17.
The stock traded up over 10% in the pre-market in reaction to the Buy rating and price target.
The $2.30 area has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $2.40, $2.60 and then $2.80.
Below $2.30, targets to the downside are $2.20, a gap fill at $2.17 and then $2.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
